We wish the best to Confluence Pharmaceuticals LLC, which licenses technology through Indiana University Research and Technology Corp.
According to Inside Indiana Business, the company is within a few months of beginning clinical trials for its drug that could treat Fragile X Syndrome. FXS affects about 180,00 people in the United States. People affected by FXS may have language, learning or social impairments.
Learn more about the company, its $1.3 million in funding and its drug Acamprosate in the IIB article here.
Leave a Reply